Table 2.

Incidence rate and HRs of MALOs associated with numbers and individual traits of the MetS present at baseline in patients with T2D

	Events/patients, n	Incidence rate per 1,000 person-years	Crude HR (95% CI)	aHR (95% CI)
Total population	3,215/230,996	1.44
A: Number of MetS traits
1 (only T2D)	29/5,794	0.56	Reference	Reference
≥2	3,186/225,202	1.46	2.55 (1.77–3.68)	2.33 (1.53–3.54)
2	609/56,664	1.07	1.86 (1.28–2.70)	1.55 (1.01–2.38)
3	1,109/77,706	1.47	2.56 (1.77–3.70)	2.35 (1.54–3.59)
4	926/61,632	1.57	2.74 (1.89–3.97)	2.69 (1.76–4.11)
5	471/25,369	2.01	3.56 (2.44–5.18)	3.42 (2.22–5.27)
6	71/3,831	2.12	3.78 (2.45–5.83)	4.09 (2.50–6.68)
Continuous MetS			1.22 (1.18–1.25)	1.28 (1.23–1.33)
B: Individual MetS traits
No albuminuria	2,421/185,618	1.33	Reference	Reference
Albuminuria	794/45,378	1.92	1.46 (1.34–1.58)	1.23 (1.13–1.35)
No hypertension	68/17,620	0.48	Reference	Reference
Hypertension	3,147/213,376	1.50	3.02 (2.37–3.83)	2.06 (1.57–2.71)
No hypertriglyceridemia	1,569/116,948	1.36	Reference	Reference
Hypertriglyceridemia	1,646/114,048	1.51	1.11 (1.03–1.19)	1.11 (1.02–1.20)
No low HDL level	2,589 /193,644	1.36	Reference	Reference
Low HDL level	626/37,352	1.86	1.38 (1.26–1.51)	1.37 (1.23–1.51)
No obesity	1,584/123,547	1.31	Reference	Reference
Obesity	1,631/107,449	1.59	1.23 (1.14–1.31)	1.38 (1.28–1.50)

A: The model was adjusted for numbers of MetS traits (continuous), age, sex, smoking status, diabetes duration, HbA_1c level, CKD, CVD, eGFR, LDL level, hyperlipidemia, any diabetes treatment use, insulin, GLP-1RAs, and SGLT-2 inhibitors. B: The model was adjusted for albuminuria, hypertension, hypertriglyceridemia, low HDL levels, obesity, age, sex, smoking status, diabetes duration, HbA_1c level, CKD, CVD, eGFR, LDL level, hyperlipidemia, any diabetes treatment use, insulin, GLP-1RAs, and SGLT-2 inhibitors.